Oscar Health (OSCR) CTO and director reports Class A share sales
Rhea-AI Filing Summary
Oscar Health insider activity: A director and President of Technology & CTO of Oscar Health, Inc. reported pre-planned trades in Class A common stock under a Rule 10b5-1 trading plan adopted on September 23, 2025. On January 2, 2026, he converted 59,800 shares of Class B common stock into Class A stock and then sold 137,933 Class A shares at a weighted average price of $15.02. On January 5, 2026, he converted an additional 86,893 Class B shares into Class A stock and sold 96,928 Class A shares at a weighted average price of $15.64. After these transactions, he directly beneficially owned 350,180 shares of Class A common stock and continued to hold additional economic interests through convertible Class B shares and family trusts as described. The filing notes that Class B shares are convertible one-for-one into Class A and will mandatorily convert after a specified period or upon certain events.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 86,893 | $0.00 | -- |
| Conversion | Class A Common Stock | 86,893 | $0.00 | -- |
| Sale | Class A Common Stock | 96,928 | $15.64 | $1.52M |
| Conversion | Class B Common Stock | 59,800 | $0.00 | -- |
| Conversion | Class A Common Stock | 59,800 | $0.00 | -- |
| Sale | Class A Common Stock | 137,933 | $15.02 | $2.07M |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
Footnotes (1)
- The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025. The Class B common stock is convertible at any time at the option of the holder into Class A common stock on a one-to-one basis, subject to certain exceptions, and will mandatorily convert into Class A common stock on the date that is seven years from the date of the prospectus used in connection with the Issuer's initial public offering and upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.42 to $15.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Mr. Schlosser disclaims beneficial ownership over the shares held of record by the trust except to the extent of his pecuniary interest therein, if any.
FAQ
What insider transactions did Oscar Health (OSCR) report in this Form 4?
The filing reports that a director and President of Technology & CTO converted Class B common stock into Class A common stock and sold Class A shares in multiple transactions on January 2 and January 5, 2026, under a Rule 10b5-1 trading plan.
What is the relationship of the reporting person to Oscar Health (OSCR)?
The reporting person is a director of Oscar Health, Inc. and serves as Officer with the title President of Technology & CTO.
Were the Oscar Health (OSCR) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).